Graft and Grit
Live
Funding

Isomorphic Labs secures $5 billion Series C funding

Isomorphic Labs has raised $5 billion in a Series C round led by Greenoaks and Sequoia Capital to accelerate its AI-driven drug discovery engine and advance therapeutic candidates toward clinical trials.

Isomorphic Labs has raised $5 billion in a Series C round led by Greenoaks and Sequoia Capital to accelerate its...

Isomorphic Labs announced a $5 billion Series C financing round on Tuesday. The round was co-led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz, Alphabet, and existing investors including Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund. This massive investment, which follows a $2.1 billion Series B round just six months prior in May, will accelerate the company's AI drug design engine and therapeutic pipeline.

Founded in 2021 by Sir Demis Hassabis and spun out of Google DeepMind, Isomorphic Labs is headquartered in London. The company leverages AI, including DeepMind's AlphaFold software, to help drug discovery, focusing on areas like cancer and immune disorders. Its core technology is a proprietary AI drug design engine called IsoDDE, which unifies foundational simulation models that work across multiple therapeutic areas and drug modalities.

Strategic use of funds and expansion plans

The new capital will be directed toward several strategic initiatives. A primary focus is maturing and scaling the IsoDDE engine. The company also plans to expand into new biology with advanced AI models and build AI-first translational and clinical development infrastructure. Also, Isomorphic Labs is creating a partner ecosystem dedicated to advancing the understanding of mechanistic disease biology.

Sir Demis Hassabis, founder and CEO, stated that the funding enables accelerating foundational biology models and systemic disease understanding, while also advancing therapeutic programs to clinical trials. Max Jaderberg, President of Isomorphic Labs, said the company makes repeatable scientific advancements weekly using its AI models, which translates into better molecular profiles and potential new medicines.

Clinical timeline and program pipeline

The company aims to begin testing its first drugs in clinical studies before the end of 2026. Regulatory filings for its initial oncology program are progressing as planned. Isomorphic currently has more than 20 programs underway across its multi-modality pipeline. The company indicated it will have further news to announce in 2027.

Konstantine Buhler, a Partner at Sequoia Capital, said Isomorphic Labs is building foundational technology for the future of medicine and praised the team's translation of AI into drug candidates. The IsoDDE engine explores vast chemical spaces to design, refine, and deliver engineered molecules with optimal drug-like properties. Its simulation models provide predictions approaching experimental accuracy.

The planned start of clinical trials for the first drugs before the end of 2026 marks the next critical phase for the AI-driven biotech.

Topics

#Funding

Related coverage

More from Funding